Your idea will be subject to a 2 stage assessment consisting of this application and an interview panel.
Projects need to demonstrate that the capital investment grant they are requesting will:
- advance the UK’s ability to manufacture genomic analysis technologies
- encourage partnerships between public and private organisation
- maximise further investment
We support organisations that can set out a clear vision of how they will encourage partnerships with companies, universities and other research establishments. You should detail the new products that you will manufacture as a result of the capital investment.
You must have a clear plan for the translation and commercialisation of any research that the capital enables you to conduct. To maximise the impact of this investment, applicants should build on existing UK infrastructure and not recreate capabilities without justification.
Examples of in-scope applications include, but are not limited to, bids that aim to:
- create an infrastructure that will fast-track the research, development, production and commercialisation of genomics or nucleic acid analysis and diagnosis technologies
- increase the UK commercial capacity production of these technologies
- increase the competitiveness of the lead company as a manufacturer
Technologies within scope, which can include physical and digital analysis tools, include (but are not limited to) those that offer advances in:
- longer-read lengths or greater accuracy, in nucleic acid sequencing technologies
- purification, selection or amplification technologies
- epigenetic analysis platforms, such as analysis of DNA methylation patterns
- diagnostics products based on genetic signatures or variation for hospital, primary care, or field use
- pathogen identification
- integration across 'omics technologies, for example, technologies which integrate data generated from multiple 'omics analysis streams (genomics, proteomics, metabolomics, transcriptomics)
The equipment to be manufactured can be either laboratory-based, or portable and field-deployable and enable genomic analysis with minimal sample preparation.
Technologies which can find end users in niche areas such as research, environment and justice are eligible. Also eligible are technologies ready for larger scale use in healthcare markets. In both these instances the product must focus on human health applications in the longer term.
The technology should represent a significant step-change over existing equipment options and offer disruptive market potential.